Larazotide - Alba Therapeutics

Drug Profile

Larazotide - Alba Therapeutics

Alternative Names: AT-1001 - Alba Therapeutics; INN-202; INN-217; Larazotide acetate; SPD 550

Latest Information Update: 20 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Maryland School of Medicine
  • Developer Alba Therapeutics; Alba Therapeutics Corporation; Innovate Biopharmaceuticals; Teva Pharmaceutical Industries; University of Virginia School of Medicine
  • Class Anti-inflammatories; Antihyperglycaemics; Hepatoprotectants; Oligopeptides
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase II Coeliac disease
  • Preclinical Non-alcoholic steatohepatitis
  • Research Gastrointestinal disorders
  • No development reported Crohn's disease; Irritable bowel syndrome
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 13 Nov 2018 Larazotide - Innovate Biopharmaceuticals is available for licensing as of 13 Nov 2018
  • 12 Nov 2018 Pharmacodynamics data from preclinical trials for Non-alcoholic steatohepatitis (NASH) released by Innovate Biopharmaceuticals
  • 31 Oct 2018 Innovate Biopharmaceuticals plans phase III trials for Coeliac disease (PO) in the first half of 2019 (PO, Capsule) (NCT03569007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top